Please login to the form below
LaingBuisson
This page shows the latest LaingBuisson news and features for those working in and with pharma, biotech and healthcare.
Latest appointments
-
LaingBuisson names chairman and CEO
LaingBuisson names chairman and CEO. Former Health Secretary Stephen Dorrell and Henry Elphick join. ... LaingBuisson, a UK healthcare market intelligence provider, has named Stephen Dorrell and Henry Elphick as its chairman and chief executive officer,
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
